Next Article in Journal
Effects of a Structured Multicomponent Physical Exercise Intervention on Quality of Life and Biopsychosocial Health among Chilean Older Adults from the Community with Controlled Multimorbidity: A Pre–Post Design
Previous Article in Journal
An Exploratory Study in Non-Professional Football on the Perception of Stakeholders about the New Working Professional Profile of Sports Kinesiologist
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJERPH
Volume 19
Issue 23
10.3390/ijerph192315841
ijerph-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Effects of the Interaction between Affective Temperaments and BIS/BAS on Depressive Symptoms in Individuals with Major Depressive Disorder

by
Kuniyoshi Toyoshima
1,*,
Jiro Masuya
2,
Miki Ono
2,
Mina Honyashiki
2,
Shogo Hashimoto
1,
Ichiro Kusumi
1 and
Takeshi Inoue
2
1
Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan
2
Department of Psychiatry, Tokyo Medical University, Tokyo 160-0023, Japan
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2022, 19(23), 15841; https://doi.org/10.3390/ijerph192315841
Submission received: 17 November 2022 / Accepted: 22 November 2022 / Published: 28 November 2022
(This article belongs to the Section Mental Health)
Browse Figure
Versions Notes

Abstract

:
Depressive symptoms (DepS) associated with major depressive disorder (MDD) are influenced by affective temperaments (ATs), behavioral inhibition system (BIS), and behavioral activation system (BAS). However, the effect of interactions between ATs and BIS/BAS on DepS in MDD remains poorly understood. Herein, we aimed to investigate the effects of these interactions. The Temperament Evaluation of Memphis, Pisa, Paris, and San Diego Auto-questionnaire (TEMPS-A), BIS/BAS questionnaire, and Patient Health Questionnaire-9 (PHQ-9) were used to evaluate ATs, BIS/BAS, and DepS, respectively, in 90 participants with MDD. Data were analyzed using hierarchical multiple regression analysis to assess the interaction effect. The interaction (β = 0.199, p < 0.05) between depressive temperament (DepT) (β = 0.319, p < 0.01) and BIS scores (β = 0.300, p < 0.01) exhibited a significant positive effect on DepS (ΔR2 = 0.038, p < 0.05). However, the interaction between ATs and BAS scores did not exhibit a significant effect on DepS. Our findings suggest that interactions between BIS sensitivity and DepT worsen DepS in individuals with MDD. Hence, to manage DepS associated with BIS sensitivity and DepT, evaluating their interaction may be useful in daily clinical practice. This study presents important insights into MDD psychopathology.

1. Introduction

Major depressive disorder (MDD) is a common and multifactorial illness, with a heritability of 30–50% [1,2,3]. The onset of MDD negatively impacts the quality of life and psychosocial functioning of individuals. Furthermore, the burden of MDD is high [4]. The following correlated risk factors have been reported in MDD: parental depression, being female, neuroticism, childhood maltreatment, dysfunctional cognitions, interpersonal dysfunction, stressful life events, insomnia, and chronic or severe physical illness [5,6,7,8,9,10]. Furthermore, vulnerability and resilience are associated with MDD onset [11,12]. However, the interrelations of the abovementioned correlated risk factors remain unclear. Notably, the association among temperament, personality, and depression onset in terms of the psychopathology of MDD is yet to be clarified.
Affective temperaments (ATs) are trait markers that demonstrate potential mood psychopathology and greatly impact people with mood disorders throughout their lives [13,14]. The domains of ATs, such as depressive (DepT), cyclothymic (CycT), hyperthymic (HypT), irritable (IrrT), and anxious (AnxT) temperaments, are identified using the Temperament Evaluation Memphis, Pisa, Paris, and San Diego Auto-questionnaire (TEMPS-A) [15,16]. Rovai et al. [17] reported a positional gap in clinical psychiatry between HypT, which is the most functional temperament, and CycT, DepT, IrrT, and AnxT, which have been more closely correlated with mood disorders. Although cultural factors can affect the expression of ATs [14], CycT and IrrT develop on a continuum of temperaments, from healthy through MDD to bipolar disorder [18]. CycT and AnxT are factors of differential diagnosis between MDD and bipolar disorder in Japan and are associated with the diagnosis of bipolar disorder [19]. In Japanese patients with MDD, the severity of depressive symptoms (DepS) is considered directly influenced by DepT, CycT, IrrT, and AnxT [20]. A previous study in Japan suggests that DepT, CycT, IrrT, and AnxT are positively correlated with DepS while only AnxT can independently predict the severity of DepS in patients with MDD [20]. This finding is consistent with those of previous studies conducted elsewhere [21,22]. ATs (DepT, CycT, IrrT, and AnxT) also mediate the impact of childhood abuse on adulthood DepS in patients with MDD [20]. Therefore, these ATs are considered a mediator of DepS in patients with MDD. However, the role of ATs in the psychopathology of MDD remains unknown.
From the perspective of human behavior, there are two distinct systems that provide the basis for human action: behavioral activation system (BAS) and behavioral inhibition system (BIS) [23]. The BIS and BAS are relevant to the motivation of avoiding aversive outcomes and the pursuance of goal-oriented outcomes, respectively [23]. Notably, individuals with MDD exhibit overactive BIS and deficient BAS functioning [24]. ATs and BIS/BAS are complementary but distinct entities in individuals with mood disorders [25]. Nevertheless, the relationship between ATs and BIS/BAS in individuals with MDD is not well understood.
Previously, the effects of the interactions among BIS, BAS, temperament, and other factors on DepS have been investigated. A nonclinical sample was employed to examine the effects of the interactions between ATs and stress [26], the quality of childhood parental bonding [27], and functional disability [28] on DepS. Furthermore, the effects of the interaction between BIS/BAS and stress on DepS were investigated, and a negative effect of the interaction between BAS and negative life events on DepS was reported [29]. ATs exhibit stronger effects on mood disorders than BIS/BAS on DepS [25]. However, the effects of the interaction between ATs and BIS/BAS on DepS in individuals with MDD have not been thoroughly investigated. Therefore, this study aimed to investigate the interaction effects using hierarchical multiple regression analysis.

2. Materials and Methods

2.1. Study Design and Setting

Individuals were invited to participate in this cross-sectional study using a convenience sampling method at Hokkaido University Hospital in Japan from July to December 2011. This study examined the dataset of Hokkaido University in Sapporo City. Patients are referred to Hokkaido University Hospital from across Japan as it is a tertiary medical institution. Several questionnaires were distributed among the dataset of the study to evaluate ATs, DepS, and BIS/BAS and to collect information regarding the demographic characteristics of the participants, including sex, age, education, marital and employment statuses, and familial psychiatric history. The completed questionnaires were returned anonymously via mail to our study group to ensure confidentiality. This study was approved by the Ethics Committee of Hokkaido University Hospital (Approval Number: 010-0041) and followed the Declaration of Helsinki. After thoroughly explaining the research, all participants provided written informed consent. Both outpatients and inpatients were included. The inclusion criteria were as follows: (1) diagnosed with MDD using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR); (2) adults aged ≥20 years; (3) being able to perform the assessments; and (4) being able to consent to participate in the study. The exclusion criteria for this study were as follows: (1) being unable to perform the assessments owing to a serious mental condition; (2) having an organic psychiatric illness; (3) having a substance-use disorder; and (4) having an axis II disorder, diagnosed using DSM-IV-TR. This research is part of more extensive studies wherein some scales were used [26,30].

2.2. Demographic Data

The demographic information of the participants, including their age, sex, marital status, educational level, employment status, familial psychiatric history, and type of MDD, were recorded.

3. Assessments

DepS, ATs, and BIS/BAS were evaluated using the PHQ-9, TEMPS-A, and BIS/BAS scales, respectively.

3.1. Depressive Symptoms

The PHQ-9 is a valid and reliable tool for assessing depression severity [31] and is widely used in mental health assessment to screen for depression [32]. The Japanese version has been validated [33] and used to assess depression severity in patients with MDD [34]. The PHQ-9 used here comprised nine items scored on a 4-point scale from 0 to 3, and the optimal cutoff point of ≥10 had a sensitivity of 92.5% and specificity of 77.0% in the Japanese version [34], similar to the original version (sensitivity of 88% and specificity of 88% for MDD) [31]. In this study, the PHQ-9 scores ranged from 0 to 27, with lower scores indicating mild DepS [31,34].

3.1.1. Affective Temperaments

The TEMPS-A is a yes-or-no questionnaire comprising 110 items designed to assess temperamental variation [15]. Cronbach’s α coefficients for DepT, CycT, HypT, IrrT, and AnxT were 0.69, 0.84, 0.79, 0.83, and 0.87, respectively, for the Japanese 110-item version of TEMPS-A [35]. Cronbach’s α for a 39-item version of TEMPS-A with 12 CycT, eight DepT, eight IrrT, eight HypT, and three AnxT subscales was 0.91 (CycT), 0.81 (DepT), 0.77 (IrrT), 0.76 (HypT), and 0.67 (AnxT) [16]. The 39-item Japanese short version of the TEMPS-A was used in this study [19,36].

3.1.2. Behavioral Inhibition System/Behavioral Activation System

The BIS/BAS scale is used to evaluate the sensitivity of behavioral inhibition/activation tendencies [23]. It comprises 20 items, each rated on a 4-point Likert scale from 1 (strongly disagree) to 4 (strongly agree). The BIS scale comprised seven items (total score range, 7–28), and the BAS scale comprised 13 items (total score range, 13–52) divided into the following subscales: representing reward responsiveness (BAS–RR: five items; score range, 5–20), drive toward appetitive goals (BAS–D: four items; score range, 4–16), and fun-seeking (BAS–FS: four items; score range, 4–16). The validity and reliability of the BIS/BAS Japanese version were demonstrated, and Cronbach’s α was calculated as follows: 0.80 (BIS), 0.76 (BAS–D), 0.65 (BAS–FS), 0.63 (BAS–RR), and 0.81 (BAS total score) [37].

3.2. Statistical Analysis

Data were stored, described, and analyzed using SPSS for Windows version 25.0 and STATA/MP 16. Pearson’s correlation analyses used Bonferroni correction to adjust probability (p) values to investigate the correlation among PHQ-9, TEMPS-A, and BIS/BAS scores. Multiple regression analyses (forced entry) were performed, with the PHQ-9 score as the dependent variable and the TEMPS-A and BIS/BAS scores as independent variables. Moderation analysis was employed to investigate the interaction effects (Figure 1A), and hierarchical multiple regression analysis was performed in two steps [38]. Before conducting hierarchical multiple regression analysis, the TEMPS-A and BIS/BAS scores were centered to deal with multicollinearity [39]. Factors 1 (TEMPS-A subscore) and 2 (BIS/BAS score) were examined as independent variables in the first step of hierarchical multiple regression analysis. Subsequently, an interaction term (factor 1 × factor 2) was introduced as an independent variable and analyzed alongside factors 1 and 2. The R2 change (ΔR2) was calculated from the first to the second step to evaluate the statistical significance of the interaction effect. In detail, if the ΔR2 was statistically significant, it indicated that an interaction effect was statistically significant. Two-sided p values were reported in this study, and p < 0.05 was considered statistically significant.
The moderated regression framework in the present study was as follows:
Severity of DepS (PHQ-9 score) = b0 + b1 (factor 1) + b2 (factor 2) + b3 (factor 1 × factor 2),
where
b0 is an intercept,
b1 is a coefficient related to the effect of factor 1,
b2 is a coefficient related to the effect of factor 2, and
b3 is a coefficient related to the interaction effect, which is the product of the two variables (factors 1 and 2) [26].

4. Results

4.1. Sample Characteristics

The primary findings are presented in Table 1. The mean (SD, standard deviation) age was 46.19 (10.73), and the average number of years of education was 13.91 (2.43). Of the 90 participants, 60 (66.67%) were male, 56 (62.22%) were married, 61 (67.78%) were currently employed, and 34 (37.78%) had a familial psychiatric history. In terms of the MDD type, 40 (44.44%) were diagnosed with a single episode of MDD and 50 (55.56%) with recurrent episodes of MDD at the time of assessment.
The clinical assessment scores are also mentioned in Table 1. The mean (SD) PHQ-9 score was 9.77 (6.84), close to the cutoff point [34]. The mean (SD) scores for TEMPS-A DepT was 1.49 (0.21), for TEMPS-A CycT was 1.29 (0.23), for TEMPS-A IrrT was 1.18 (0.16), and for TEMPS-A AnxT was 1.39 (0.25), which were higher than the average values of the same scores of individuals without MDD. The mean (SD) TEMPS-A HypT score was 1.18 (0.17), which was nearly identical to that of individuals without MDD [36]. The mean (SD) scores for BIS was 20.77 (5.13), for BAS–D was 9.97 (2.95), and for BAS–RR was 14.10 (3.13), which were nearly identical to those of individuals without MDD. The mean (SD) scores for total BAS was 32.62 (7.45) and for BAS–FS was 8.49 (2.51), which were lower than the average values of the scores of individuals without MDD [37].

4.2. Correlations between Measures

The results of Pearson’s correlation analyses are demonstrated in Table 2. The correlation analyses revealed that higher PHQ-9 scores correlated with higher DepT (r = 0.47, p < 0.001), CycT (r = 0.35, p = 0.047), IrrT (r = 0.45, p < 0.001), AnxT (r = 0.50, p < 0.001), and BIS (r = 0.43, p = 0.001) scores. The PHQ-9 scores did not significantly correlate with HypT, total BAS, BAS–D, BAS × RR, and BAS–FS scores.

4.3. Moderation Analysis (N = 90)

The results of moderation analysis are demonstrated in Table 3 and Figure 1B. A significant positive interaction (β = 0.199, p = 0.033) between DepT scores (β = 0.319, p = 0.004) and BIS scores (β = 0.300, p = 0.007) was observed, which had an effect on PHQ-9 scores (ΔR2 = 0.038, p = 0.033). However, no other combinations of BIS/BAS scores and TEMPS-A subscores exhibited a significant effect on PHQ-9 scores.
The variable represents the standardized regression coefficient (standardized β), except ΔR2 and adjusted R2. Table 3 shows the statistical variables from the second step but not from the first.

5. Discussion

We believe that the effect of the interaction between BIS sensitivity and DepT increases the severity of DepS in individuals with MDD. Notably, no significant interaction was observed between BIS sensitivity and other ATs and between BAS sensitivity and any ATs. This is the first study to report the effect of the interaction between BIS and DepT on DepS in Japanese patients with MDD. Theoretically, on the time axis, trait markers exist earlier than state markers. Therefore, ATs and BIS/BAS precede DepS. Based on this theory, we discussed how the interaction between ATs and BIS/BAS affected DepS.
From the perspective of AT, the findings of this study suggests that DepT interacts with BIS sensitivity, thereby affecting DepS in the individuals with MDD. DepT has also been related to having a history of childhood abuse and working disability, which increases the severity of DepS in adults [26,28]. DepT varies between individuals with and without MDD, with it being higher in the former than in the latter [18]. Therefore, DepT may interact with childhood abuse and working disability, thereby affecting DepS in individuals with MDD, and the interaction effects may be stronger than in individuals without MDD. In the future, we want to further investigate these interaction effects in individuals with MDD.
Regarding BIS sensitivity, our results indicate that BIS interacts with DepT, thereby affecting DepS in individuals with MDD. Although a previous study found that individuals with MDD exhibited higher BIS sensitivity than those without MDD [24], the BIS sensitivity of our participants (BIS total score = 20.77 ± 5.13) was similar to that of individuals without MDD (BIS total score = 21.38 ± 4.17) [37]. Of the participants, 55.56% were diagnosed with recurrent MDD, which may have influenced the BIS sensitivity results. In general, recurring psychopathology or depression can indicate a more severe form of MDD. Furthermore, the high number of recurrences may suggest bipolarity [40]. Hence, the possibility of bipolarity could prevent increased BIS sensitivity [41,42]. Despite this limitation, our findings suggest that BIS enhances the depressogenic effect of DepT, even in the group exhibiting moderate BIS sensitivity in MDD. According to a previous study, higher BIS sensitivity prevents the improvement of symptoms in individuals with MDD [43]. Furthermore, the effects of the interaction between BIS and DepT may prevent MDD improvement by increasing the depressogenic effect of DepT. In the future, we want to conduct a longitudinal study to investigate these causal relationships.
The effects of the interaction between BIS sensitivity and DepT can be associated with the treatment responsiveness of individuals with MDD. Personality characteristics, such as low reward dependence or cooperativeness, have been considered risk factors for treatment-resistant MDD [44]. However, the influence of the interaction between ATs and BIS/BAS on the response rates and/or remission rates in MDD has not been investigated. Recently, the use of precision psychotherapy to achieve personalized psychiatry has been receiving attention [45]. A previous study suggests that the sensitivity change in BIS/BAS is associated with responsiveness to antidepressants and remission rates in individuals with MDD [46].
Furthermore, psychological intervention may be effective for depression; however, no significant changes in BIS/BAS sensitivity were observed [47]. Therefore, the BIS/BAS sensitivity change may be more susceptible to pharmaceutical rather than psychotherapeutic interventions. These data suggest that individuals with MDD and high BIS sensitivity and DepT may be resistant to both antidepressant treatment and psychotherapy. In future studies, we would like to investigate whether the change in BIS/BAS sensitivity in response to pharmacological and psychological interventions could be differentiated using ATs in individuals with MDD. Additionally, a future longitudinal study is warranted to investigate the prognosis of individuals with Midland both high BIS sensitivity and DepT.
The current research has several limitations:
  • Owing to the cross-sectional design of the study, we could not determine the causal relationships among the variables.
  • Because our sample included twice as many men as women and was recruited in a tertiary care setting, the generalizability of our findings to all individuals with MDD may be restricted.
  • All the study participants were adults, thereby preventing generalization to individuals under the age of 20 years.
  • Memory bias could have influenced the results of the self-reported assessments used in this study. Although most questions in these assessments were regarding the last few weeks or days, negative autobiographical memories caused by depression may have influenced the results of the questionnaires used in this study.
  • The effects of medication on the results were not considered.
  • The present study was conducted in Japan. Hence, generalizability to other countries may be limited.
  • This study lacked information regarding genes associated with MDD [48].
  • A previous study suggested that affective temperament and BIS/BAS are complementary but distinct entities [25]. Neuroticism may exhibit confounding effects on the relationship between BIS/BAS–AT–depression and between BIS–AT–depression [25]. However, we did not assess neuroticism in the present study. Hence, the regression models could not be extended, which could constitute a limitation of this study.
Despite these limitations, this is the first study regarding the effects of the interaction between BIS/BAS and ATs on DepS in individuals with MDD.

6. Conclusions

This study suggests that the effects of the interaction between BIS sensitivity and DepT worsen DepS in individuals with MDD. In a clinical setting, such interactions may be useful in addressing DepS associated with both BIS sensitivity and DepT. Our study presents important insights into the psychopathology of individuals with MDD.

Author Contributions

Conceptualization: K.T., J.M., M.O., M.H., S.H., I.K. and T.I. Data curation: K.T., J.M., M.O., M.H., S.H., I.K. and T.I. Formal analysis: K.T. and T.I. Funding acquisition: K.T. and T.I. Investigation: K.T., J.M., M.O., M.H., S.H., I.K. and T.I. Methodology: K.T., J.M., M.O., M.H., S.H., I.K. and T.I. Project administration: K.T., J.M., M.O., M.H., S.H., I.K. and T.I. Resources: K.T. and T.I. Software: K.T. and T.I. Supervision: I.K. and T.I. Validation: K.T., J.M. and T.I. Visualization: K.T. and T.I. Roles/writing: original draft—K.T. and T.I. Writing—review and editing: K.T., J.M., M.O., M.H., S.H., I.K. and T.I. All authors have read and agreed to the published version of the manuscript.

Funding

This work was partially supported by a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (Grant 16K10194) to T.I.; Research and Development Grants for Comprehensive Research for Persons with Disabilities from the Japan Agency for Medical Research and Development (Grant JP18dk0307060) to T.I.; SENSHIN Medical Research Foundation to T.I.; and JSPS KAKENHI (Grant JP20K16662) to K.T.

Institutional Review Board Statement

This research was approved by the Ethics Committee of Hokkaido University Hospital (Approval Number: 010-0041). All study procedures were performed in accordance with the principles in the Declaration of Helsinki.

Informed Consent Statement

All subjects provided written informed consent after receiving an explanation about this study.

Data Availability Statement

The datasets generated during and/or analyzed during the current study are available upon reasonable request from the corresponding author.

Acknowledgments

The authors thank their colleagues at Tokyo Medical University and Hokkaido University.

Conflicts of Interest

Takeshi Inoue is a member of the advisory boards of Pfizer, Novartis Pharma, and Mitsubishi Tanabe Pharma. He has received personal fees from Mochida Pharmaceutical, Takeda Pharmaceutical, Eli Lilly, Janssen Pharmaceutical, MSD, Taisho Toyama Pharmaceutical, Yoshitomiyakuhin, and Daiichi Sankyo; grants from Shionogi, Astellas, Tsumura, and Eisai; and grants and personal fees from Otsuka Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Kyowa Pharmaceutical Industry, Pfizer, Novartis Pharma, and Meiji Seika Pharma. Yota Fujimura received research and grant support from Novartis Pharma, Otsuka Pharmaceutical, Astellas, Dainippon Sumitomo Pharma, and Shionogi. Ichiro Kusumi has received honoraria from Eisai, Eli Lilly, Janssen Pharmaceutical, Meiji Seika Pharma, Mochida Pharmaceutical, Novartis Pharma, Otsuka Pharmaceutical, Shionogi, Sumitomo Pharma, Takeda Pharmaceutical, Viatris, and Yoshitomiyakuhin and research/grant support from Asahi Kasei Pharma, Astellas, Daiichi Sankyo, Eisai, Eli Lilly, Mochida Pharmaceutical, Nihon Medi-Physics, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Pharma, Takeda Pharmaceutical, and Tanabe Mitsubishi Pharma. Jiro Masuya has received personal compensation from Otsuka Pharmaceutical, Eli Lilly, Astellas, and Meiji Yasuda Mental Health Foundation and grants from Pfizer. Other authors do not have any actual or potential conflict of interest.

References

  1. Otte, C.; Gold, S.M.; Penninx, B.W.; Pariante, C.M.; Etkin, A.; Fava, M.; Mohr, D.C.; Schatzberg, A.F. Major depressive disorder. Nat. Rev. Dis. Prim. 2016, 2, 16065. [Google Scholar] [CrossRef] [Green Version]
  2. Malhi, G.S.; Mann, J.J. Depression. Lancet 2018, 392, 2299–2312. [Google Scholar] [CrossRef] [PubMed]
  3. Kendall, K.M.; Van Assche, E.; Andlauer, T.F.M.; Choi, K.W.; Luykx, J.J.; Schulte, E.C.; Lu, Y. The genetic basis of major depression. Psychol Med. 2021, 51, 2217–2230. [Google Scholar] [CrossRef] [PubMed]
  4. Lam, R.W.; McIntosh, D.; Wang, J.L.; Enns, M.; Kolivakis, T.; Michalak, E.E. (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder. Can. J. Psychiatry 2016, 61, 510–523. [Google Scholar] [CrossRef] [PubMed]
  5. Kendler, K.S.; Kuhn, J.; Prescott, C.A. The interrelationship of neuroticism, sex, and stressful life events in the prediction of episodes of major depression. Am. J. Psychiatry 2004, 161, 631–636. [Google Scholar] [CrossRef]
  6. Li, L.; Wu, C.; Gan, Y.; Qu, X.; Lu, Z. Insomnia and the risk of depression: A meta-analysis of prospective cohort studies. BMC Psychiatry 2016, 16, 375. [Google Scholar] [CrossRef] [Green Version]
  7. Read, J.R.; Sharpe, L.; Modini, M.; Dear, B.F. Multimorbidity and depression: A systematic review and meta-analysis. J. Affect. Disord. 2017, 221, 36–46. [Google Scholar] [CrossRef]
  8. Hammen, C. Risk factors for depression: An autobiographical review. Annu. Rev. Clin. Psychol. 2018, 14, 1–28. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Tsaras, K.; Papathanasiou, I.V.; Mitsi, D.; Veneti, A.; Kelesi, M.; Zyga, S.; Fradelos, E.C. Assessment of depression and anxiety in breast cancer patients: Prevalence and associated factors. Asian Pac. J. Cancer Prev. 2018, 19, 1661–1669. [Google Scholar] [CrossRef] [PubMed]
  10. Li, M.; Liu, S.; D’Arcy, C.; Gao, T.; Meng, X. Interactions of childhood maltreatment and genetic variations in adult depression: A systematic review. J. Affect. Disord. 2020, 276, 119–136. [Google Scholar] [CrossRef]
  11. Southwick, S.M.; Vythilingam, M.; Charney, D.S. The psychobiology of depression and resilience to stress: Implications for prevention and treatment. Annu. Rev. Clin. Psychol. 2005, 1, 255–291. [Google Scholar] [CrossRef] [PubMed]
  12. Han, M.H.; Nestler, E.J. Neural substrates of depression and resilience. Neurotherapeutics 2017, 14, 677–686. [Google Scholar] [CrossRef] [Green Version]
  13. Kawamura, Y.; Akiyama, T.; Shimada, T.; Minato, T.; Umekage, T.; Noda, Y.; Ukawa, K.; Hashidume, C.; Sakai, Y.; Otowa, T.; et al. Six-year stability of affective temperaments as measured by TEMPS-A. Psychopathology 2010, 43, 240–247. [Google Scholar] [CrossRef]
  14. Elias, L.R.; Köhler, C.A.; Stubbs, B.; Maciel, B.R.; Cavalcante, L.M.; Vale, A.M.O.; Gonda, X.; Quevedo, J.; Hyphantis, T.N.; Soares, J.C.; et al. Measuring affective temperaments: A systematic review of validation studies of the Temperament Evaluation in Memphis Pisa and San Diego (TEMPS) instruments. J. Affect. Disord. 2017, 212, 25–37. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Akiskal, H.S.; Akiskal, K.K.; Haykal, R.F.; Manning, J.S.; Connor, P.D. TEMPS-A: Progress towards validation of a self-rated clinical version of the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire. J. Affect. Disord. 2005, 85, 3–16. [Google Scholar] [CrossRef]
  16. Akiskal, H.S.; Mendlowicz, M.V.; Jean-Louis, G.; Rapaport, M.H.; Kelsoe, J.R.; Gillin, J.C.; Smith, T.L. TEMPS-A: Validation of a short version of a self-rated instrument designed to measure variations in temperament. J. Affect. Disord. 2005, 85, 45–52. [Google Scholar] [CrossRef]
  17. Rovai, L.; Maremmani, A.G.; Rugani, F.; Bacciardi, S.; Pacini, M.; Dell’Osso, L.; Akiskal, H.S.; Maremmani, I. Do Akiskal & Mallya’s affective temperaments belong to the domain of pathology or to that of normality? Eur. Rev. Med. Pharmacol. Sci. 2013, 17, 2065–2079. [Google Scholar] [PubMed]
  18. Solmi, M.; Zaninotto, L.; Toffanin, T.; Veronese, N.; Lin, K.; Stubbs, B.; Fornaro, M.; Correll, C.U. A comparative meta-analysis of TEMPS scores across mood disorder patients, their first-degree relatives, healthy controls, and other psychiatric disorders. J. Affect. Disord. 2016, 196, 32–46. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Morishita, C.; Kameyama, R.; Toda, H.; Masuya, J.; Fujimura, Y.; Higashi, S.; Kusumi, I.; Inoue, T. TEMPS-A (short version) plays a supplementary role in the differential diagnosis between major depressive disorder and bipolar disorder. Psychiatry Clin. Neurosci. 2021, 75, 166–171. [Google Scholar] [CrossRef] [PubMed]
  20. Toda, H.; Inoue, T.; Tsunoda, T.; Nakai, Y.; Tanichi, M.; Tanaka, T.; Hashimoto, N.; Takaesu, Y.; Nakagawa, S.; Kitaichi, Y.; et al. Affective temperaments play an important role in the relationship between childhood abuse and depressive symptoms in major depressive disorder. Psychiatry Res. 2016, 236, 142–147. [Google Scholar] [CrossRef]
  21. Karam, E.G.; Salamoun, M.M.; Yeretzian, J.S.; Mneimneh, Z.N.; Karam, A.N.; Fayyad, J.; Hantouche, E.; Akiskal, K.; Akiskal, H.S. The role of anxious and hyperthymic temperaments in mental disorders: A national epidemiologic study. World Psychiatry 2010, 9, 103–110. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Kesebir, S.; Gündoğar, D.; Küçüksubaşı, Y.; Tatlıdil Yaylacı, E. The relation between affective temperament and resilience in depression: A controlled study. J. Affect. Disord. 2013, 148, 352–356. [Google Scholar] [CrossRef] [PubMed]
  23. Carver, C.S.; White, T.L. Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: The BIS/BAS scales. J. Personal. Soc. Psychol. 1994, 67, 319–333. [Google Scholar] [CrossRef]
  24. Kasch, K.L.; Rottenberg, J.; Arnow, B.A.; Gotlib, I.H. Behavioral activation and inhibition systems and the severity and course of depression. J. Abnorm. Psychol. 2002, 111, 589–597. [Google Scholar] [CrossRef] [PubMed]
  25. Van Meter, A.R.; Youngstrom, E.A. A tale of two diatheses: Temperament, BIS, and BAS as risk factors for mood disorder. J. Affect. Disord. 2015, 180, 170–178. [Google Scholar] [CrossRef]
  26. Nakai, Y.; Inoue, T.; Chen, C.; Toda, H.; Toyomaki, A.; Nakato, Y.; Nakagawa, S.; Kitaichi, Y.; Kameyama, R.; Wakatsuki, Y.; et al. The moderator effects of affective temperaments, childhood abuse and adult stressful life events on depressive symptoms in the nonclinical general adult population. J. Affect. Disord. 2015, 187, 203–210. [Google Scholar] [CrossRef]
  27. Toyoshima, K.; Inoue, T.; Masuya, J.; Fujimura, Y.; Higashi, S.; Kusumi, I. Interaction between childhood parental bonding and affective temperaments on adulthood depressive symptoms. J. Affect. Disord. Rep. 2021, 3, 100056. [Google Scholar] [CrossRef]
  28. Toyoshima, K.; Inoue, T.; Masuya, J.; Fujimura, Y.; Higashi, S.; Kusumi, I. Affective temperaments and functional disability modulate depressive symptoms in adulthood. J. Affect. Disord. Rep. 2021, 4, 100108. [Google Scholar] [CrossRef]
  29. Toyoshima, K.; Inoue, T.; Kameyama, R.; Masuya, J.; Fujimura, Y.; Higashi, S.; Kusumi, I. BIS/BAS as moderators in the relationship between stressful life events and depressive symptoms in adult community volunteers. J. Affect. Disord. Rep. 2021, 3, 100050. [Google Scholar] [CrossRef]
  30. Nakai, Y.; Inoue, T.; Toda, H.; Toyomaki, A.; Nakato, Y.; Nakagawa, S.; Kitaichi, Y.; Kameyama, R.; Hayashishita, Y.; Wakatsuki, Y.; et al. The influence of childhood abuse, adult stressful life events and temperaments on depressive symptoms in the nonclinical general adult population. J. Affect. Disord. 2014, 158, 101–107. [Google Scholar] [CrossRef]
  31. Kroenke, K.; Spitzer, R.L.; Williams, J.B. The PHQ-9: Validity of a brief depression severity measure. J. Gen. Intern. Med. 2001, 16, 606–613. [Google Scholar] [CrossRef] [PubMed]
  32. Costantini, L.; Pasquarella, C.; Odone, A.; Colucci, M.E.; Costanza, A.; Serafini, G.; Aguglia, A.; Belvederi Murri, M.; Brakoulias, V.; Amore, M.; et al. Screening for depression in primary care with Patient Health Questionnaire-9 (PHQ-9): A systematic review. J. Affect. Disord. 2021, 279, 473–483. [Google Scholar] [CrossRef] [PubMed]
  33. Muramatsu, K.; Miyaoka, H.; Kamijima, K.; Muramatsu, Y.; Yoshida, M.; Otsubo, T.; Gejyo, F. The patient health questionnaire, Japanese version: Validity according to the mini-international neuropsychiatric interview-plus. Psychol. Rep. 2007, 101 Pt 1, 952–960. [Google Scholar] [CrossRef] [PubMed]
  34. Muramatsu, K.; Miyaoka, H.; Kamijima, K.; Muramatsu, Y.; Tanaka, Y.; Hosaka, M.; Miwa, Y.; Fuse, K.; Yoshimine, F.; Mashima, I.; et al. Performance of the Japanese version of the Patient Health Questionnaire-9 (J-PHQ-9) for depression in primary care. Gen. Hosp. Psychiatry 2018, 52, 64–69. [Google Scholar] [CrossRef]
  35. Matsumoto, S.; Akiyama, T.; Tsuda, H.; Miyake, Y.; Kawamura, Y.; Noda, T.; Akiskal, K.K.; Akiskal, H.S. Reliability and validity of TEMPS-A in a Japanese non-clinical population: Application to unipolar and bipolar depressives. J. Affect. Disord. 2005, 85, 85–92. [Google Scholar] [CrossRef] [PubMed]
  36. Nakato, Y.; Inoue, T.; Nakagawa, S.; Kitaichi, Y.; Kameyama, R.; Wakatsuki, Y.; Kitagawa, K.; Omiya, Y.; Kusumi, I. Confirmation of the factorial structure of the Japanese short version of the TEMPS-A in psychiatric patients and general adults. Neuropsychiatr. Dis. Treat. 2016, 12, 2173–2179. [Google Scholar] [CrossRef] [Green Version]
  37. Takahashi, Y.; Yamagata, S.; Kijima, N.; Shigemasu, K.; Ono, Y.; Ando, J. Gray’s temperament model: Development of Japanese version of BIS/BAS scales and a behavior genetic investigation using the twin method. Jpn. J. Personal. 2007, 15, 276–289. [Google Scholar] [CrossRef]
  38. Caspi, A.; Sugden, K.; Moffitt, T.E.; Taylor, A.; Craig, I.W.; Harrington, H.; McClay, J.; Mill, J.; Martin, J.; Braithwaite, A.; et al. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 2003, 301, 386–389. [Google Scholar] [CrossRef] [PubMed]
  39. Aiken, L.S.; West, S.G. Multiple Regression: Testing and Interpreting Interactions; SAGE: Newbury Park, CA, USA, 1991. [Google Scholar]
  40. Ghaemi, S.N.; Dalley, S. The bipolar spectrum: Conceptions and misconceptions. Aust. N. Z. J. Psychiatry 2014, 48, 314–324. [Google Scholar] [CrossRef]
  41. Meyer, B.; Johnson, S.L.; Winters, R. Responsiveness to threat and incentive in bipolar disorder: Relations of the BIS/BAS scales with symptoms. J. Psychopathol. Behav. Assess. 2001, 23, 133–143. [Google Scholar] [CrossRef] [PubMed]
  42. Alloy, L.B.; Abramson, L.Y.; Walshaw, P.D.; Cogswell, A.; Grandin, L.D.; Hughes, M.E.; Iacoviello, B.M.; Whitehouse, W.G.; Urosevic, S.; Nusslock, R.; et al. Behavioral Approach System and Behavioral Inhibition System sensitivities and bipolar spectrum disorders: Prospective prediction of bipolar mood episodes. Bipolar Disord. 2008, 10, 310–322. [Google Scholar] [CrossRef] [PubMed]
  43. Brown, T.A. Temporal course and structural relationships among dimensions of temperament and DSM-IV anxiety and mood disorder constructs. J. Abnorm. Psychol. 2007, 116, 313–328. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Takahashi, M.; Shirayama, Y.; Muneoka, K.; Suzuki, M.; Sato, K.; Hashimoto, K. Personality traits as risk factors for treatment-resistant depression. PLoS ONE 2013, 8, e63756. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Martinez-Aran, A.; Vieta, E. Precision psychotherapy. Eur. Neuropsychopharmacol. 2022, 55, 20–21. [Google Scholar] [CrossRef]
  46. Allen, T.A.; Lam, R.W.; Milev, R.; Rizvi, S.J.; Frey, B.N.; MacQueen, G.M.; Müller, D.J.; Uher, R.; Kennedy, S.H.; Quilty, L.C. Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: A CAN-BIND-1 report. Psychol. Med. 2019, 49, 1629–1638. [Google Scholar] [CrossRef]
  47. Takahashi, T.; Sugiyama, F.; Kikai, T.; Kawashima, I.; Guan, S.; Oguchi, M.; Uchida, T.; Kumano, H. Changes in depression and anxiety through mindfulness group therapy in Japan: The role of mindfulness and self-compassion as possible mediators. Biopsychosoc. Med. 2019, 13, 4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Kishi, T.; Yoshimura, R.; Kitajima, T.; Okochi, T.; Okumura, T.; Tsunoka, T.; Yamanouchi, Y.; Kinoshita, Y.; Kawashima, K.; Fukuo, Y.; et al. SIRT1 gene is associated with major depressive disorder in the Japanese population. J. Affect. Disord. 2010, 126, 167–173. [Google Scholar] [CrossRef] [PubMed]
Ijerph 19 15841 g001 550
Figure 1. (A) Conceptual diagram of the interaction using moderation analysis. (B) Effects of the interaction between behavioral inhibition system sensitivity and depressive temperament on depressive symptoms in individuals with major depressive disorder (N = 90). D, direct effect; I, interaction effect; P, positive interaction effect; +, increasing the severity of depressive symptoms.
Figure 1. (A) Conceptual diagram of the interaction using moderation analysis. (B) Effects of the interaction between behavioral inhibition system sensitivity and depressive temperament on depressive symptoms in individuals with major depressive disorder (N = 90). D, direct effect; I, interaction effect; P, positive interaction effect; +, increasing the severity of depressive symptoms.
Ijerph 19 15841 g001
Table
Table 1. Basic findings (N = 90).
Table 1. Basic findings (N = 90).
Demographic CharacteristicsMean (SD) or N (%)
Age, mean46.19 (10.73)
Sex (male/female), n60/30 (66.67/33.33)
Married, n56 (62.22)
Years of education, mean13.91 (2.43)
Currently employed, n61 (67.78)
Familial psychiatric history, n34 (37.78)
Type (single episode/recurrent), n40/50 (44.44/55.56)
ScaleMean (SD)
PHQ-99.77 (6.84)
TEMPS-A
DepT1.49 (0.21)
CycT1.29 (0.23)
HypT1.18 (0.17)
IrrT1.18 (0.16)
AnxT1.39 (0.25)
BIS20.77 (5.13)
BAS total32.62 (7.45)
BAS–D9.97 (2.95)
BAS–RR14.10 (3.13)
BAS–FS8.49 (2.51)
Note. BAS, behavioral activation system; BIS, behavioral inhibition system; D, drive; FS, fun-seeking; MDD, major depressive disorder; PHQ-9, Patient Health Questionnaire-9; RR, reward responsiveness; RUD, recurrent unipolar depression; SD, standard deviation; TEMPS-A, Temperament Evaluation of Memphis, Pisa, Paris, and San Diego Auto-questionnaire (depressive [DepT], cyclothymic [CycT], hyperthymic [HypT], irritable [IrrT], and anxious [AnxT] temperaments).
Table
Table 2. Pearson’s correlation analysis (N = 90).
Table 2. Pearson’s correlation analysis (N = 90).
12345678910
1. PHQ-9—
2. DepT0.47 ***—
3. CycT0.35 *0.41 **—
4. HypT−0.08−0.090.06—
5. IrrT0.45 ***0.51 ***0.60 ***−0.06—
6. AnxT0.50 ***0.61 ***0.60 ***−0.150.68 ***—
7. BIS0.43 **0.54 ***0.40 **−0.230.41 **0.57 ***—
8. BAS total0.100.120.200.44 **0.150.100.20—
9. BAS–D0.050.080.130.39 **0.150.070.150.87 ***—
10. BAS–RR0.090.190.180.35 *0.060.120.300.88 ***0.64 ***—
11. BAS–FS0.12−0.010.220.42 **0.160.03−0.010.83 ***0.58 ***0.60 ***
* p < 0.05, ** p < 0.01, *** p < 0.001.
Table
Table 3. Moderation analysis (N = 90).
Table 3. Moderation analysis (N = 90).
Dependent Factor: PHQ-9 Score
Affective Temperaments
Independent variablesDepTCycTHypTIrrTAnxT
TEMPS-A score0.319 **0.197−0.0050.315 **0.370 **
BIS0.300 **0.358 **0.439 ***0.308 **0.254 *
Interaction0.199 *0.014−0.0750.0440.134
ΔR20.038 *0.0000.0050.0020.017
Adjusted R20.2800.1970.1660.2540.276
DepTCycTHypTIrrTAnxT
TEMPS-A score0.484 ***0.341 **−0.1740.456 ***0.498 ***
BAS total0.0550.0250.1660.0240.047
Interaction0.126−0.0080.0460.0810.022
ΔR20.0150.0000.0020.0060.000
Adjusted R20.2090.089−0.0060.1800.226
DepTCycTHypTIrrTAnxT
TEMPS-A score0.470 ***0.344 **−0.1460.457 ***0.502 ***
BAS–D0.0060.0030.096−0.0290.011
Interaction0.1070.0090.0710.0770.044
ΔR20.0110.0000.0040.0060.002
Adjusted R20.2040.089−0.0180.1790.226
DepTCycTHypTIrrTAnxT
TEMPS-A score0.493 ***0.341 **−0.1090.462 ***0.508 ***
BAS–RR0.0100.0230.1240.0490.022
Interaction0.1020.002−0.0260.0950.043
ΔR20.0100.0000.0010.0090.002
Adjusted R20.2020.089−0.0130.1850.226
DepTCycTHypTIrrTAnxT
TEMPS-A score0.493 ***0.344 **−0.1810.450 ***0.496 ***
BAS–FS0.1410.0340.1820.0570.102
Interaction0.143−0.0380.0530.074−0.013
ΔR20.0190.0010.0020.0050.000
Adjusted R20.2270.0920.0020.1800.235
* p < 0.05, ** p < 0.01, *** p < 0.001.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Toyoshima, K.; Masuya, J.; Ono, M.; Honyashiki, M.; Hashimoto, S.; Kusumi, I.; Inoue, T. Effects of the Interaction between Affective Temperaments and BIS/BAS on Depressive Symptoms in Individuals with Major Depressive Disorder. Int. J. Environ. Res. Public Health 2022, 19, 15841. https://doi.org/10.3390/ijerph192315841

AMA Style

Toyoshima K, Masuya J, Ono M, Honyashiki M, Hashimoto S, Kusumi I, Inoue T. Effects of the Interaction between Affective Temperaments and BIS/BAS on Depressive Symptoms in Individuals with Major Depressive Disorder. International Journal of Environmental Research and Public Health. 2022; 19(23):15841. https://doi.org/10.3390/ijerph192315841

Chicago/Turabian Style

Toyoshima, Kuniyoshi, Jiro Masuya, Miki Ono, Mina Honyashiki, Shogo Hashimoto, Ichiro Kusumi, and Takeshi Inoue. 2022. "Effects of the Interaction between Affective Temperaments and BIS/BAS on Depressive Symptoms in Individuals with Major Depressive Disorder" International Journal of Environmental Research and Public Health 19, no. 23: 15841. https://doi.org/10.3390/ijerph192315841

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop